Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 4/20 | 0.40 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18538093 | 0.82 | PDE2A (0.34) | NTRK1ALDH1A1CHRNA7PDE2A | |
| SCHEMBL18527091 | 0.80 | AGBL2 (0.42) | NTRK1AGBL2ALDH1A1KMT2ANR3C1 | |
| SCHEMBL18540664 | 0.72 | CHRNA7 (0.43) | NTRK1AGBL2SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL18538037 | 0.70 | LRRK2 (0.37) | NTRK1AGBL2SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL18527151 | 0.68 | NR3C1 (0.32) | NR3C1 | |
| SCHEMBL26093582 | 0.66 | SMN1; SMN2 (0.43) | AGBL2SMN1; SMN2KDM4EALDH1A1KMT2A | |
| SCHEMBL18737714 | 0.66 | POLB (0.49) | AGBL2SMN1; SMN2KDM4EALDH1A1KMT2A | |
| SCHEMBL9795320 | 0.65 | KMT2A (0.58) | SMN1; SMN2KDM4EKMT2APOLBLMNA | |
| SCHEMBL23612094 | 0.64 | KDM4E (0.40) | NTRK1AGBL2KDM4E | |
| SCHEMBL25848123 | 0.64 | HSD17B10 (0.41) | SMN1; SMN2KDM4EALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017031325-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | FORUM PHARMACEUTICALS INC. (US) | 2017-02-23 | — | — | WO | disclosed |
| US-20170050980-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | DENALI THERAPEUTICS, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170050980-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | DENALI THERAPEUTICS, INC. | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050980-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | PSEN2, SMN1; SMN2, OTC | NTRK1 1009/4885AGBL2 1091/4885SMN1; SMN2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.